NAD+ 1000MG

1. Sirtuin Activation (SIRT1–7)

Sirtuins are NAD+-dependent protein deacylases (class III histone deacetylases). They bind NAD+ and an acetylated target protein, cleaving the glycosidic bond to release nicotinamide (NAM) and generate O-acetyl-ADP-ribose. Km range: 94–888 µM.[6]

• SIRT1 Pathway: Deacetylates PGC-1α → mitochondrial biogenesis; FOXO → stress resistance; also deacetylates LKB1 → activates AMPK → positive feedback loop increasing NAD+ and fatty acid oxidation[6]
• SIRT3 Pathway: Mitochondrial localization; deacetylates MnSOD → enhanced antioxidant defense; activates OXPHOS enzymes[6]

2. PARP1/2 DNA Repair

PARP1 detects DNA strand breaks → consumes NAD+ to build poly(ADP-ribose) chains → recruits repair enzymes (XRCC1). Km 20–97 µM — higher affinity than sirtuins, can outcompete for NAD+ during DNA damage. Excessive activation → NAD+/ATP depletion → parthanatos (cell death).[6][7]

3. CD38/CD157 Hydrolysis

CD38 is the major regulator of tissue NAD+ levels (Km ~15–25 µM). It hydrolyzes NAD+ into NAM and ADP-ribose, and cyclizes NAD+ into cADPR → Ca²⁺ mobilization from intracellular stores. CD38 expression increases with aging, directly driving NAD+ decline.[1][8]

4. SARM1 Axonal NADase

SARM1 contains a TIR domain with intrinsic NADase activity. Activated by nerve injury → rapid axonal NAD+ depletion → local metabolic collapse and calcium influx → Wallerian degeneration.[7]

5. Extracellular Signaling

Extracellular NAD+ acts at P2X7 purinergic receptors on T-regulatory cells → ART2-P2X7 pathway → immune modulation.[6]

Precursor Entry Mechanisms

Precursor	Cellular Entry	Notes
NAD+ (direct)	Cannot passively cross plasma membrane	Exception: Connexin 43 in heart muscle
NR	Equilibrative nucleoside transporters (ENTs)	Best oral bioavailability; GRAS status
NMN	Dephosphorylated → NR by CD73 extracellularly	Slc12a8 transporter in small intestine
NAM	Passive diffusion	Feedback-inhibits sirtuins/PARPs at high doses

Substrate Competition & Tissue NAD+ Dynamics

The relative Km values of the three NAD+-consuming enzyme classes (PARP1 20-97 µM, sirtuins 94-888 µM, CD38 ~15-25 µM) determine which pathway dominates under given cellular conditions. CD38's low Km positions it as the major regulator of tissue NAD+ levels under baseline conditions, while PARP1 outcompetes sirtuins during acute DNA-damage events. Excessive PARP1 activation can deplete NAD+ to the point of ATP collapse and parthanatos cell death. CD38 expression rises with aging — driving the 10-65% NAD+ decline observed in aged human brain, liver, and skin tissues. Tarragó 2018 demonstrated that CD38 inhibition (78c compound) in 32-month-old mice restored tissue NAD+ across liver, muscle, and heart, reversing age-associated metabolic dysfunction — establishing CD38 inhibition as a parallel pharmacologic strategy to NAD+ precursor supplementation.[1][8]

Microbiome-Mediated Bioavailability

Christen 2025 head-to-head trial (n=65) demonstrated that orally-administered NMN and NR are extensively metabolized by gut microbiota into nicotinic acid (NA) intermediates before systemic uptake — explaining why intracellular NAD+ rises despite limited direct intestinal absorption of intact NMN/NR. This finding reframes earlier debate over NMN-versus-NR bioavailability as largely a question of microbiome composition rather than transporter expression, and helps explain inter-subject variability observed across earlier trials. Equivalent-dose nicotinamide (NAM) failed to elevate NAD+, consistent with NAM's role as a sirtuin-feedback inhibitor at high concentrations.[4]

NAD+ research spans aging biology, metabolic disease, neurodegeneration, and cardiovascular health with 15+ clinical trials and extensive preclinical data:

1. Aging and Longevity — Declining NAD+ is a hallmark of aging; supplementation mimics caloric restriction, rejuvenates stem cells, extends healthspan in mice.[3][9]
2. Metabolic Disorders — NMN increased muscle insulin sensitivity 25% in prediabetic women (Yoshino 2021, Science); NR prevented diet-induced obesity 40% in mice.[10][11]
3. Neurodegenerative Diseases — Alzheimer's (NMN → restored spatial memory), Parkinson's (NADPARK: NR → increased cerebral NAD+, MRS-confirmed), ALS (NR + pterostilbene → improved function).[12][13]
4. Cardiovascular Health — Heart failure, cardiomyopathy, ischemia-reperfusion; NMN restores capillary density/endurance 80% in aged mice (SIRT1-dependent vascular rejuvenation).[14]
5. DNA Repair / Cancer — NAD+ is sole PARP substrate; complex dual role in genomic stability vs tumor metabolism.[7]
6. Immune Modulation — CD38 on macrophages drives M1/M2 polarization; CD38 inhibitors (78c, apigenin) reverse age-related NAD+ decline.[8]
7. Acute Organ Injury — NMN protects against cisplatin-induced AKI (SIRT1-dependent); intranasal NAD+ reduces brain infarct volume post-ischemia.[15]
8. Ophthalmology — Photoreceptor survival, retinal degeneration, glaucoma.[2]
9. Muscle Performance — Dose-dependent VO₂ improvement in amateur runners (NMN 600/1200 mg); grip strength in elderly.[16]
10. Fertility — NMN restores oocyte quality, improves ovulation, rescues fertility in aged female mice.[2]
11. CD38 Pathway Pharmacology — Tarragó 2018 (78c CD38 inhibitor in aged mice) and apigenin/luteolin natural CD38 inhibitors used as research tools to dissect CD38-mediated NAD+ decline separate from precursor supplementation.[8]
12. Microbiome-Pharmacokinetic Studies — Christen 2025 head-to-head NMN vs NR vs NAM (n=65) established gut-bacterial NA intermediates as the dominant route of intracellular NAD+ replenishment, reframing precursor-bioavailability research toward microbiome composition.[4]

Comparative Research Context

NAD+ research occupies the intersection of three adjacent fields: mitochondrial biology and bioenergetics, aging and longevity pharmacology, and signaling-enzyme cofactor biochemistry. The signature pharmacology — sirtuin / PARP / CD38 / SARM1 substrate competition with widely different Km values — distinguishes NAD+ from receptor-targeted aging interventions and supports its use as a tool molecule for dissecting how cells partition a finite cofactor pool across competing enzymatic demands. Researchers comparing NAD+ precursor pharmacology with related mitochondrial and longevity peptides commonly cross-reference our MOTS-c, Glutathione, SS-31, and Epithalon pages for parallel mitochondrial-protective, antioxidant, and geroprotector pharmacology. The Mills 2016 long-term mouse study, Yoshino 2021 prediabetic-women trial, Brakedal 2022 NADPARK Parkinson's trial, and Christen 2025 head-to-head precursor study together establish NAD+ pharmacology as one of the best-characterized longevity intervention programs in current research.